CAP

B. Braun's Space® Infusion Pump Systems Earn UL 2900-2-1 Certification

Retrieved on: 
Thursday, December 1, 2022

BETHLEHEM, Pa., Dec. 1, 2022 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the wireless devices of the Space Infusion Pump System* earned certification to UL 2900-2-1** through UL Cybersecurity Assurance Program (UL CAP). The UL 2900-2-1 standard is published as a U.S. national consensus standard by the American National Standards Institute (ANSI) and a recognized consensus standard by the U.S. Food and Drug Administration (FDA) supporting their pre- and post-market cybersecurity guidance.

Key Points: 
  • BETHLEHEM, Pa., Dec. 1, 2022 /PRNewswire/ -- B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the wireless devices of the Space Infusion Pump System* earned certification to UL 2900-2-1** through UL Cybersecurity Assurance Program (UL CAP).
  • The technical experts at UL Solutions explored all facets of the UL 2900-2-1 Standard requirements in their evaluation of the Space Infusion Pump Systems for CAP certification.
  • In addition to receiving certification to the UL 2900-2-1 Standard, Perfusor Syringe Pump,within B. Braun's Space Infusion Pump Systems platform, is the first in the industry with medical ground and/or air transport in the FDA cleared indications for use.
  • * Space Infusion Pump System includes the Wireless Infusomat 8713051U, SpaceStation with SpaceCom 8713142U, and Perfusor 8713031U.

Theralink® Technologies Accepted to Present Two Posters at the Upcoming San Antonio Breast Cancer Symposium

Retrieved on: 
Thursday, December 1, 2022

GOLDEN, Colo., Dec. 1, 2022 /PRNewswire/ -- Theralink Technologies (OTC: THER) ("Theralink" or the "Company"), a precision oncology company with a novel quantitative protein and phosphoprotein-based assay for breast cancer, today announced the acceptance of two poster presentations evaluating the potential use and utility of its novel RPPA (Reverse Phase Protein Array) technology at the San Antonio Breast Cancer Symposium (SABCS) 2022.

Key Points: 
  • Mick Ruxin M.D., CEO of Theralink Technologies stated, "We are so pleased to have multiple poster presentations accepted at SABCS this year.
  • During our presentations we will highlight the potential of our innovative RPPA-based technology for clinical molecular profiling of breast cancer patients.
  • The Theralink Assay for Advanced Breast Cancer can provide additional levels of quantified clarity for patients who need it the most."
  • The Theralink management team welcomes the opportunity to meet with you in-person in San Antonio at SABCS 2022.

CENTOGENE to Participate in Upcoming Conferences in December

Retrieved on: 
Thursday, December 1, 2022

CENTOGENEs mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases.

Key Points: 
  • CENTOGENEs mission is to provide data-driven, life-changing answers to patients, physicians, and pharma companies for rare and neurodegenerative diseases.
  • We integrate multiomic technologies with the CENTOGENE Biodatabank providing dimensional analysis to guide the next generation of precision medicine.
  • Since our founding in 2006, CENTOGENE has been offering rapid and reliable diagnosis building a network of approximately 30,000 active physicians.
  • To date, the CENTOGENE Biodatabank has contributed to generating novel insights for more than 260 peer-reviewed publications.

AnPac Announces Regaining Compliance with Nasdaq Listing Requirement

Retrieved on: 
Wednesday, November 30, 2022

On June 9, 2022, AnPac Bio-Medical Science Co., Ltd. (the Company) received the determination from The Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the requirements to remain listed in The Nasdaq Capital Market subject to a one-year Mandatory Panel Monitor of the Companys ongoing compliance with such requirements as set force in Listing Rule 5815(d)(4)(B).

Key Points: 
  • On June 9, 2022, AnPac Bio-Medical Science Co., Ltd. (the Company) received the determination from The Nasdaq Stock Market LLC (Nasdaq) that the Company has regained compliance with the requirements to remain listed in The Nasdaq Capital Market subject to a one-year Mandatory Panel Monitor of the Companys ongoing compliance with such requirements as set force in Listing Rule 5815(d)(4)(B).
  • The Company will have the opportunity to respond/present to the Hearings Panel as provided by Listing Rule 5815(d)(4)(C).
  • This request was due to a Staff determination letter (the Letter) on September9, 2022 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (Nasdaq) notifying the Company of the Staffs determination to delist the Companys securities from The Nasdaq Capital Market due to the Companys failure to regain compliance with the $1 per share bid price requirement of Listed Securities required for continued listing as set forth in Listing Rule5450(a)(1)(the $1 Bid Rule), following the 180 calendar day compliance period set forth in Listing Rule5810(c)(3)(A)(the Compliance Period).
  • On September16, 2022, Company received a letter from Nasdaq granting the appeal and scheduling the Nasdaq Hearings Panel for October20, 2022.

Theralink® Technologies Announces Closing of Private Placement and Conversion of Existing Convertible Notes and Convertible Preferred Shares

Retrieved on: 
Tuesday, November 29, 2022

Additionally, in connection with this offering, holders of certain existing convertible notes and convertible preferred shares of the Company agreed to convert their securities into an aggregate of approximately $13.4 million of the senior secured convertible debentures and warrants on the terms described in the foregoing paragraph.

Key Points: 
  • Additionally, in connection with this offering, holders of certain existing convertible notes and convertible preferred shares of the Company agreed to convert their securities into an aggregate of approximately $13.4 million of the senior secured convertible debentures and warrants on the terms described in the foregoing paragraph.
  • Joseph Gunnar & Co., LLC is acting as the sole placement agent for the offering.
  • Theralink is a proteomics-based, precision medicine company with a CLIA-certified and CAP accredited laboratory located in Golden, Colorado.
  • The Company undertakes no obligation to publicly release statements made to reflect events or circumstances after the date hereof.

Perform[cb] Announced as #1 Network for Consumer Financial Services by mThink

Retrieved on: 
Tuesday, November 29, 2022

SARASOTA, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Perform[cb], voted #1 CPA Network overall for six years running, has just been named #1 Network for Consumer Financial Services in mThink's inaugural Blue Book survey of the financial services vertical.

Key Points: 
  • SARASOTA, Fla., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Perform[cb], voted #1 CPA Network overall for six years running, has just been named #1 Network for Consumer Financial Services in mThink's inaugural Blue Book survey of the financial services vertical.
  • With deep expertise throughout the consumer financial space, Perform[cb] is the first network to be recognized as a leader in this growing vertical.
  • This newest vertical-specific Blue Book survey was launched as a way for mThink, publisher of the Revenue + Performance Blue Book, to provide more granular information and up-to-date industry insights to marketers and affiliate partners in niches such as mobile marketing, health and wellness, and consumer financial services.
  • "Earning the title of #1 Network for Consumer Financial Services in mThink's first vertical-specific Blue Book survey is a testament to our expert team's dedication across the financial industry.

SmartHealth Diagnostics Appoints Accomplished Corporate and Finance Leader Mitch Levine as President, Chief Financial Officer, and Director

Retrieved on: 
Tuesday, November 29, 2022

IRVINE, Calif., Nov. 29, 2022 /PRNewswire/ -- SmartHealth Diagnostics, Inc. ("SHDx" or "the Company"), formerly Predictive Health Diagnostics Company, a leading developer of precision diagnostics that address unmet clinical needs in vascular, metabolic, and oncological diseases, today announced the appointment of Mitch Levine as President, Chief Financial Officer, and member of the Board of Directors.

Key Points: 
  • Mr. Levine brings a combined 40 years of strategic leadership experience in corporate life sciences, investment management, and investment banking, including extensive expertise in fundraising for growth-stage companies.
  • Prior to joining SmartHealth Diagnostics, Mr. Levine spent five years as CFO of Oncocyte Corp., a Nasdaq-listed molecular diagnostics company, and is currently an advisor.
  • He also was responsible for creating a critical licensing and tech transfer agreement with one of China's largest and fastest growing diagnostic labs.
  • In his early career, Mr. Levine held roles of progressive responsibility with Bear Stearns and Lehman Brothers.

KSL | Pulse Scientific Named National Distributor in Canada for First-of-its-Kind COVID-19 & Flu At-Home Molecular Test

Retrieved on: 
Tuesday, November 29, 2022

The Lucira COVID-19 & Flu Test is a 99% accurate rapid molecular test that delivers results in 30 minutes or less from one shallow nasal swab.

Key Points: 
  • The Lucira COVID-19 & Flu Test is a 99% accurate rapid molecular test that delivers results in 30 minutes or less from one shallow nasal swab.
  • View the full release here: https://www.businesswire.com/news/home/20221129005267/en/
    KSL | Pulse Scientific named national distributor in Canada for first-of-its-kind Covid-19 & Flu at-home molecular test.
  • Developed by Lucira Health, this 99% accurate test approved by Health Canada is now available for the COVID/Flu season.
  • Because Australia had an alarming spike in COVID and flu cases and we could see a substantial increase in North America.

PreCheck Health Services Showcases New Hereditary and Somatic Cancer Testing Capabilities at the A4M World Congress with Support From Pierian

Retrieved on: 
Tuesday, November 29, 2022

By supporting hereditary cancer testing, patients can now benefit from the advantages of NGS to enable more precise cancer diagnosis.

Key Points: 
  • By supporting hereditary cancer testing, patients can now benefit from the advantages of NGS to enable more precise cancer diagnosis.
  • Their first two NGS offerings are based on Illumina's TruSight Hereditary Cancer and TruSight Oncology 500 panels.
  • PreCheck Health Services will be exhibiting at the 30th annual A4M World Congress from December 9th to 11th in Las Vegas, NV at booth #3102.
  • PreCheck Health Services will be showcasing their newly validated cancer panels and offering the attendees detailed sample reports from the Pierian Clinical Genomics Workspace (CGW).

UAB Cardiogenomics Clinic and Allelica to perform polygenic risk score clinical implementation study

Retrieved on: 
Tuesday, November 29, 2022

NEW YORK, Nov. 29, 2022 /PRNewswire/ -- The UAB Cardiogenomics Clinic, led by Dr. Pankaj Arora, is partnering with the industry leader for polygenic risk score (PRS) analysis and reporting, Allelica Inc., to perform a clinical implementation study on PRS application for coronary artery disease. The aim of the study is to develop a clear path forward for the clinical implementation of PRS in cardiovascular disease prevention.

Key Points: 
  • The Cardiogenomics Clinic at the University of Alabama at Birmingham and Allelica are partnering to perform a clinical implementation study to assess how polygenic risk score integration changes clinical management and health outcomes in a US health system.
  • NEW YORK, Nov. 29, 2022 /PRNewswire/ -- The UAB Cardiogenomics Clinic, led by Dr. Pankaj Arora, is partnering with the industry leader for polygenic risk score (PRS) analysis and reporting, Allelica Inc., to perform a clinical implementation study on PRS application for coronary artery disease.
  • The aim of the study is to develop a clear path forward for the clinical implementation of PRS in cardiovascular disease prevention.
  • The results of this study will help to establish a clear pathway for providers for the clinical implementation of PRS in cardiovascular disease risk management and prevention.